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1036Objective: Management of a patent left internal thoracic artery graft during reoperation is controversial. The
‘‘no-dissection’’ technique avoids dissection and clamping of the left internal thoracic artery graft, and myocar-
dial protection is achieved using adjunctive systemic hypothermia and hyperkalemia. We compared the postop-
erative outcomes after isolated reoperative aortic valve replacement in patients with previous coronary artery
bypass grafting with a patent left internal thoracic artery graft using a no-dissection technique with the outcomes
of patients with previous coronary artery bypass grafting without a left internal thoracic artery graft.
Methods: The outcomes were analyzed for patients who underwent isolated reoperative aortic valve replace-
ment with previous coronary artery bypass grafting from January 1, 2002, to June, 30, 2011. Patency of the
left internal thoracic artery was confirmed using either coronary angiography or computed tomography angiog-
raphy. The patent left internal thoracic artery group did not undergo dissection or clamping of the left internal
thoracic artery graft, and myocardial protection was obtained using systemic hypothermia and hyperkalemia.
The no left internal thoracic artery group underwent isolated aortic valve replacement with previous coronary
artery bypass grafting but had no left internal thoracic artery graft.
Results:A total 174 patients were identified for the patent left internal thoracic artery group and 26 for the no left
internal thoracic artery group. The perfusion and crossclamp times were similar. No differences were seen be-
tween the 2 groups in operative mortality (6.9% vs 7.7%, P ¼ 1.00). The complication rates were similar, and
the peak creatine kinase-MB values within 24 hours of surgery were not significantly different between the 2
groups (median, 27.4 vs 29 m/mL; P ¼ .72).
Conclusions: Reoperative aortic valve replacement in patients with previous coronary artery bypass grafting
and a patent left internal thoracic artery graft can be performed safely without dissection or clamping of the
left internal thoracic artery using systemic hyperkalemia and hypothermia. We believe this method prevents
unnecessary injury during dissection of the left internal thoracic artery graft. (J Thorac Cardiovasc Surg
2012;144:1036-41)A left internal thoracic artery (LITA) to left anterior de-
scending artery (LAD) graft has become the standard of
practice, given its improved survival and superb long-term
patency.1 Reoperation in cardiac surgery in a patient with
a previous LITA to LAD graft is challenging for surgeons
because of the specific consideration for myocardial protec-
tion and prevention of LITA graft injury. In aortic valve re-
placement (AVR), aortic crossclamping is required, unless
hypothermic circulatory arrest is used. The most commonly
used strategy for myocardial protection in the case of a pat-
ent LITA graft has been resternotomy, dissection of thee Department of Cardiac Surgery, Brigham and Women’s Hospital, Boston,
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The Journal of Thoracic and Cardiovascular SurLITA graft, and occlusion of the graft after aortic clamping,
followed by cardioplegic arrest. The proposed advantage is
reducing cardioplegia washout in the LITA territory while
maximizing myocardial protection.2 However, dissection
of the LITA graft carries a risk of injury, with a reported
risk of injury of up to 5.3% and mortality of up to 50%.3
Another strategy is to perform reoperative surgery with-
out dissection of the LITA graft and to protect the myocar-
dium by induction of moderate to deep hypothermia (to
20C), systemic hyperkalemia, and cardioplegia.
The purpose of the present study was to evaluate the
safety of the latter ‘‘no-dissection technique’’ in patients un-
dergoing reoperative aortic valve surgery with previous cor-
onary artery bypass grafting (CABG) and a patent LITA
graft.METHODS
Patient Population
We studied patients who had undergone isolated reoperative AVR with
previous CABG from January 1, 2002, to June 30, 2011. Patients with con-
comitant coronary and/or valve surgery or an occluded or dissected LITA
were excluded. We classified patients into either the patent LITA groupgery c November 2012
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Dor the no-LITA group to compare the outcomes. Patency of the LITAwas
confirmed using either preoperative coronary angiography or computed to-
mography angiography. All preoperative data, in-hospital outcomes, and
postdischarge outcomes were collected from Brigham and Women’s Hos-
pital patient medical records and cardiac surgery database using the Society
of Thoracic Surgeons definition and criteria. The present study was ap-
proved by the institutional review board of Brigham andWomen’s hospital.
Patient consent was waived by the institutional review board.
Operative Technique
All the reviewed operations were performed using median sternotomy,
upper hemisternotomy, or right thoracotomy. The cannulation strategy was
selected on a case-by-case basis. In general, aortic cannulation and right
atrial cannulation with dual-stage venous cannula was performed. How-
ever, in most cases, a femoral or axillary artery and femoral vein were dis-
sected and cannulated to prepare for emergent need of cardiopulmonary
bypass. Cardiopulmonary bypass was instituted in most patients before
resternotomy to protect the patent LITA graft. Vacuum assistance for ve-
nous drainage was routinely applied. Access for antegrade or retrograde
or both antegrade and retrograde cardioplegia was obtained. The patent
LITA group did not undergo dissection or clamping of the LITA graft,
and myocardial protection was obtained using moderate to deep systemic
hypothermia (20C-28C) and hyperkalemia, in addition to antegrade
and/or retrograde cardioplegia. Hyperkalemia was obtained first by giving
40 mEq of potassium chloride to a pump. Next, the goal of a potassium
level greater than 6 mEq/L but less than 7 mEq/L was obtained by adding
10 to 20 mEq, as needed. Whenever cardiac activity was seen, potassium
was added until the activity ceased. If collateral back flow from the coro-
nary ostia obscured the operative field during replacement, the pump flows
were temporary decreased to approximately 500 to 1500 mL/min for sev-
eral seconds to allow suture placement to the annulus. This was used in par-
ticular near the coronary ostium; otherwise, pump suction was placed near
the ostium to provide a bloodless field. No attempts to dissect and clamp the
LITAwere made. The no-LITA group underwent isolated AVR with previ-
ous CABG, but had no LITA graft; therefore, no LITA dissection was in-
volved. AVR was performed using a standard technique. Ultrafiltration
was used to clear the high potassium level after release of the aortic cross-
clamp. De-airing in all cases was accomplished with transesophageal echo-
cardiographic guidance, and the aortic root vent was maintained open until
the patient was completely separated from cardiopulmonary bypass.
Statistical Analysis
The patient demographic data and operative and postoperative out-
comes were collected prospectively during hospitalization and coded ac-
cording to the standards of the Society of Thoracic Surgeons, version
2.52. The laboratory, echocardiographic, and transfusion data were ex-
tracted from the hospital electronic medical information systems.
Red blood cell use is presented as the percentage of cases transfused and
median and interquartile range of units transfused. Operative mortality in-
cluded any death in the hospital or within 30 days of surgery, if discharged.
Readmissions includedadmission toanyhospitalwithin30daysofdischarge.
Normally distributed continuous variables are presented as the mean 
standard deviation. Non-normally distributed continuous variables areThe Journal of Thoracic and Carpresented as medians and interquartile ranges. Analyses of continuous vari-
ables was done using Student t tests with Levine’s homogeneity of variance
or Mann-Whitney U tests, as appropriate. Dichotomous variables are pre-
sented as the percentage of cases and number of cases and were evaluated
using Fisher’s exact test. All statistical analyses were done using SPSS, ver-
sion 13.0 (SPSS, Chicago, Ill).RESULTS
We identified 200 consecutive patients who underwent
isolated reoperative AVRwith previous CABG from January
1, 2002, to June 30, 2011. Of these 200 patients, 174 were
included in the patent LITA group and 26 in the no-LITA
group.
The patient characteristics are listed in Table 1. The re-
sults showed that the no-LITA group included older patients
andmorewomen but the other characteristics, including his-
tory of cardiovascular disease, peripheral vascular disease,
renal failure, and cerebrovascular disease were similar. Car-
diogenic shock at surgery was observed in 3 patients in the
LITA group and none in the no-LITA group (P¼ 1.00). Two
patients in the LITA group (1.2%) underwent surgery on an
emergent status versus none in the no-LITA group.
In the patent LITA group, there were 10 failed prosthetic
valves (1 mechanical and 9 biologic) and 2 cases of pros-
thetic valve endocarditis. In the no-LITA group, there
were 2 failed prosthetic valves (both biologic) and 1 case
of prosthetic valve endocarditis.
The average number of patent grafts in the patent LITA
group was 2.8 (range, 1-7) and in the no-LITA group was
2.6 (range, 2-6).Intraoperative Outcomes
All patients underwent AVR using cardiopulmonary by-
pass and aortic crossclamping. The type of incisions used
was upper hemisternotomy in 101 (58.7%), right anterior
thoracotomy in 1 (0.6%), and full sternotomy (41.5%) in
72 in the LITA group. In the no-LITA group, 12 patients
had an upper hemisternotomy (46.2%), 1 patient a right an-
terior thoracotomy (3.8%), and 13 patients a full sternot-
omy (50.0%). For the arterial cannulation technique,
aortic cannulation was used in 29 (9.1%), femoral artery
cannulation in 59 (33.9%), and axillary artery cannulation
in 86 (49.4%) in the LITA group. In the no-LITA group,
aortic cannulation was used in 10 (38.4%), femoral artery
cannulation in 4 (15.4%), and axillary artery cannulation
in 12 (46.2%). For venous cannulation, 63 patients
(36.2%) in the LITA group and 9 patients (34.6%) in the
no-LITA group had femoral venous cannulation; all the
others underwent standard atrial caval, 2-stage venous can-
nulation. No strict protocol was used in the choice of cannu-
lation site. This was mainly decided by surgeon preference.
The evaluated operative factors are listed in Table 2. The
perfusion time (median, 158 vs 145 minutes; P ¼ .10)
and crossclamp time (median, 77 vs 82 minutes; P ¼ .61)diovascular Surgery c Volume 144, Number 5 1037
TABLE 1. Patient characteristics
Preoperative
characteristics
Patent
LITA (n ¼ 174)
No LITA
(n ¼ 26) P value
Mean age (y) 76.5  7.1 79.4  5.8 .052
Women 18.4 (32) 46.2 (12) .003
Family history of CAD 24.1 (42) 19.2 (5) .804
Renal failure 9.8 (17) 3.8 (1) .477
Preoperative creatinine 1.3  0.7 1.2  0.3 .407
CVA 8.1 (14) 11.5 (3) .471
PVD 32.2 (56) 19.2 (5) .254
Cardiovascular disease 25.3 (44) 23.1 (6) 1.000
Arrhythmia 13.8 (24) 7.7 (2) .540
History of MI 38.5 (67) 34.6 (9) .830
Cardiogenic shock 1.7 (3) 0.0 (0) 1.000
Emergent status 1.2 (2) 0.0 (0) .405
Expected STS mortality 6.9 (12) 6.4 (2)
Data presented as mean  standard deviation or percentages (numbers). LITA, Left
internal thoracic artery; CAD, coronary artery disease; CVA, cerebrovascular disease;
PVD, peripheral vascular disease; MI, myocardial infarction; STS, Society of
Thoracic Surgeons.
TABLE 3. Postoperative outcomes of patent LITA group and no-LITA
group
Postoperative
outcomes
Patent LITA
(n ¼ 174)
No LITA
(n ¼ 26) P value
Peak CK-MB 24 h .723
Median 27.4 29
IQR 17-69 21-38
Peak CK-MB 72 h .653
Median 28.5 29.6
IQR 17-66 21-38
Reoperation for bleeding 4.6 (8) 3.8 (1) 1.000
Permanent stroke 4.0 (7) 0.0 (0) .597
Transfused with RBCs 58.6 (102) 65.4 (17) .669
ICU stay (h) .549
Median 73.0 69.5
IQR 38-119 43-98
Ventilation time (h) .397
Median 12.0 11.1
IQR 7-30 7-8
LOS (d) .111
Median 9.0 7.0
IQR 6-14 7-8
Operative mortality 6.9 (12) 7.7 (2) 1.000
Expected STS mortality 6.9 (12) 6.4 (2)
Observed/expected ratio 1.0 1.2
Data presented as median and IQR or percentages (numbers). LITA, Left internal tho-
racic artery; CK-MB, creatine kinase-MB; IQR, interquartile range; RBC, red blood
cell; ICU, intensive care unit; LOS, length of stay; STS, Society of Thoracic Surgeons.
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red blood cells. In the LITA group, 22 patients (12.6%) un-
derwent intra-aortic balloon pump insertion. Of these, 21
were intraoperative and 1 was inserted preoperatively. In
the no-LITA group, 2 (7.7%) underwent intra-aortic bal-
loon pump insertion (P ¼ .746), 1 preoperatively and 1
intraoperatively.
Postoperative Outcomes
The postoperative outcomes are summarized in Table 3.
No differences were found between the 2 groups in opera-
tive mortality (6.9% vs 7.7%; P ¼ 1.00). When compared
using the Society of Thoracic Surgeons risk algorithms, the
observed versus expected mortality ratio was 1.0 and 1.2.
The complication rates, including reoperation for bleed-
ing (4.6% vs 3.8%, P¼ 1.00), percentage of patients trans-
fused (58.6% vs 65.4%, P ¼ .67), and intubation time
(median, 12.0 vs 11.1 hours; P ¼ .40), were similar. No
TABLE 2. Operative characteristics
Operative
characteristics
Patent
LITA (n ¼ 174)
No LITA
(n ¼ 26) P value
Perfusion time (min) .103
Median 158 145
IQR 131-204 125-194
Crossclamp time (min) .616
Median 77 82
IQR 63-98 60-114
Intraoperative IABP 12.6 (22) 7.7 (2) .746
Patients transfused with RBCs (n) 19.5 (34) 23.1 (6) .610
RBC units transfused (n) .712
Median 3.0 3.0
IQR 1-4 2-4
Data presented as median and IQR or percentages (numbers). LITA, Left internal tho-
racic artery; IQR, interquartile range; IABP, intra-aortic balloon pump; RBC, red
blood cell.
1038 The Journal of Thoracic and Cardiovascular Surdifference was seen in the stroke rate or duration of inten-
sive care unit stay.
Intraoperative injury to the LITA was encountered in 1
patient and was repaired immediately. This occurred during
mediastinal dissection; no injuries to the LITA graft oc-
curred during redo sternotomy.
We used postoperative creatine kinase (CK)-MB leakage
as a measure of the adequacy of myocardial protection. The
peak CK-MB values within 24 hours of surgery were not
significantly different (median, 27.4 vs 29 m/mL;
P¼ .72), nor were the peak CK-MB values within 72 hours
(median, 28.5 vs 29.6 m/mL; P¼ .653). No new Qwaves on
the electrocardiogram and no new asynergy on the echocar-
diogram were seen postoperatively among these patient
groups. Also, no postoperative intra-aortic balloon pump
use in either group.DISCUSSION
The use of the LITA to LAD graft has become the stan-
dard of practice and has increased survival in the coronary
artery populations. This has created a new patient popula-
tion for cardiac surgeons constituting those previous
coronary artery grafting and progressive valve disease that
ultimately requires surgical intervention, especially with
a patent LITA to LAD graft. Unlike mitral surgery or
coronary artery disease, aortic valve disease requiresgery c November 2012
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The most common strategy in these patients is to perform
resternotomy, dissect the LITA graft, and clamp the graft,
with cardioplegia given to prevent washout in the LITA ter-
ritory. This means that the border zones of perfused versus
arrested myocardium are hypothetically at greater risk of is-
chemic injury. However, injury to the LITA graft during dis-
section can have serious consequences. The rate of injury
has been reported to be 5% to 40%, with perioperativemor-
tality reported to be 9% to 50%.4-6
Several techniques during the initial surgery have been
reported to prevent LITA injury during reoperation. These
have included interposition of the lung between the chest
wall and LITA,7 the use of polytetrafluoroethylene mem-
brane to cover the LITA,8 and creating a slit in the pericar-
dium to tuck the LITA away from posterior table of the
sternum.9 A careful review of the computed tomography
scan has been used to check for the relationship between
previous clips on the pedicle and the posterior table of the
sternum and has proved beneficial.10 Early institution of
cardiopulmonary bypass during resternotomy allows easier
dissection by decompression of the heart.11 Left lateral tho-
racotomy for lateral lesions to avoid sternotomy12 and off-
pump bypass to eliminate the need for LITA dissection13
has also been reported to prevent injury to the LITA. All
these strategies can be used to reduce the risk of LITA injury
during dissection. In our practice, we perform interposition
of the lung, preoperative computed tomography, and early
institution of cardiopulmonary bypass.
In the present report, we have documented the results
with the ‘‘no-dissection technique.’’ This method leaves
the patent LITA graft open during aortic crossclamping, al-
lowing the LITA graft to perfuse during aortic valve sur-
gery. The unique feature in this method is the temperature
discrepancy of the myocardial areas. The myocardium is
protected by cardioplegia (4C), which is cooler than car-
diopulmonary bypass (20C-28C), but cardioplegia wash-
out by the patent LITA graft causes the LAD territory to
reach the same temperature as with cardiopulmonary by-
pass. Therefore, moderate to deep hypothermia is manda-
tory. In the beginning of the present study, we were
cooling to 20C; however, other reports have confirmed
safe protection with higher temperatures.14 Currently, our
practice is to cool to 28C and to cool further with the addi-
tion of hyperkalemia if uncontrollable cardiac activity oc-
curs. In addition, systemic hyperkalemia to 6 to 7 mEq/L
was obtained to maintain cardiac arrest. Although hypothet-
ically systemic hyperkalemia can reduce vascular tone by
affecting the potassium channels, this was not encountered
during our experience. If blood returning from the coronary
ostium obscures the field, we decrease the pump flow tem-
porarily to allow suture placement. This technique is
amenable to minimally invasive hemisternotomy for reo-
perative aortic valve surgery,15 in which dissection of theThe Journal of Thoracic and CarLITA graft imposes a greater risk of injury owing to its lim-
ited field. We used both antegrade and retrograde cardiople-
gia with different strategies optimized to the individual
patient findings. The access and cannulation strategy was
surgeon dependent. The rate of hemisternotomy was similar
in the 2 groups (58.7% vs 46.2%). However, the no-
dissection group underwent more femoral cannulation
(33.9% vs 19.4%) and the no-LITA group had more aortic
cannulation (9.1% vs 38.4%). This was likely owing to sur-
geon selection of femoral artery cannulation in the case of
emergency because the patients had a patent LITA and
were thought to be at high risk.
Lytle and colleagues16 first described the concept of the
no-dissection technique. Others have reported this technique
to be safe and valid. Byrne and colleagues17 reported on 94
patients undergoingAVRwith a patent LITA graft and found
a perioperative mortality of 6.4%. Smith and colleagues14
reported on 118 patients who underwent no dissection of
the LITA and compared them with 88 patients in whom the
LITA was dissected and showed no difference in mortality
but a reduction in patent graft injury. There have also been
reports using the no-dissection technique and performing
AVR with a beating heart technique with good outcomes.18
Our study showed similar perfusion and crossclamp
times with those of the control group. Also, no difference
was found in mortality. Several predictors of mortality in re-
operative surgery have been proposed, including age, low
ejection fraction, and advanced New York Heart Associa-
tion functional class,19,20 but we could not confirm these
relationships. We used postoperative CK-MB leakage as
a measure of the adequacy of myocardial protection, and
the peak CK-MB values within 24 and 72 hours of surgery
were not statistically different. Also, no ST changes were
seen in these patients. However, we encountered 1 LITA in-
jury with the ‘‘no-dissection’’ technique. This occurred dur-
ing dissection of dense adhesions and the injury occurred at
the previous LITA to LAD anastomosis. The injury was re-
paired primarily. The incidence of LITA injury was 5% in
the report by Byrne and colleagues.17 Our report showed
an even lower incidence of LITA injury (0.6%), confirming
the safety of the ‘‘no-dissection’’ technique.
Retrograde cardioplegia alone is used in reoperative car-
diac surgery with promising outcomes.21 However, theoret-
ically, the perfusion pressure in retrograde cardioplegia
(average, 25-30 mmHg) is lower than the systemic pressure
during cardiopulmonary bypass (average, 60-70 mm Hg),
which compromised myocardial protection in the patent
LITA perfusion area. Therefore, we believe our technique
with hypothermia and hyperkalemia combined with cardio-
plegia will provide better myocardial protection.
The present study had some limitations. First, this was
a retrospective study. It did include the largest series of pa-
tients undergoing this technique; however, the statistical
significance could not overcome the retrospective naturediovascular Surgery c Volume 144, Number 5 1039
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ideal and the size of the group was small. The ideal group
would be a patent LITA group that underwent dissection
of the graft. We did find 6 patients who underwent LITA dis-
section during the study period; however, that would have
been an even smaller comparison group with less value
for statistical comparison. We had 1 LITA injury among
these 6 patients who underwent LITA dissection. On the
other hand, the comparison group who had previous
CABGwithout a LITA graft will have complete myocardial
protection through antegrade cardioplegia. Thus, no coro-
nary blood flow originating distal to the aortic crossclamp
is present to wash out the cardioplegia, and good cardiople-
gia perfusion to the LAD area is provided that will not be
provided in patients with a dissected or patent LITA. That
the CK-MB levels were comparable those in this well-
protected group indicates the safety of the no-dissection
technique.CONCLUSIONS
Patients undergoing AVR after CABG in the presence of
a patent LITA are at high risk of injury. Although the com-
mon practice has been to dissect the graft and clamp to
achieve full myocardial protection, there is a danger of graft
injury during dissection. The ‘‘no-dissection’’ technique
demonstrated no increase in mortality and morbidity and
is an effective strategy using hypothermia and systemic hy-
perkalemia to counteract the cardioplegia washout effect.References
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Dr Richard Shemin (Los Angeles, Calif). Thank you very
much for a beautiful presentation and for bringing this very large
series to our forum today.
Obviously, the topic is driven by the desire, number 1, to totally
eliminate any injury to the LITA and, number 2, to try to increase
the number of minimally invasive or minimal access approaches in
the re-do CABG population who come for valve replacement. You
showed some data at the risk of injury to the LITA and you quoted
data from the 1980s and 1990s showing it was 40% to 50% and in
the modern era it may be 5%, but I personally submit that, if we
look at the re-do CABG rate in which patent LITAs are almost rou-
tine, that the rate of 5% is still an overestimate, particularly with
routine CT scanning to really know whether or not you have a tho-
racic artery that is stuck behind the sternum. I think the major con-
tributions of your paper are the size of the series, 176 patients—
there are other series in the literature, I think this is the largest
one; the fact that half these patients did have a mini-sternotomy,
which is a very important part of the series; your good outcomes,
which obviously is very important; and your ability to show that
leaving the LITA open actually allowed decent or goodmyocardial
protection.
I have a few concerns and a few questions for you.
First of all, when I review a series in which the treatment group
is 174 patients and 26 patients in the control group, I really worry
whether that is an adequate comparison and whether or not any of
the statistics between the 2 groups are really legitimate. I am not
sure you are really powered to do any comparison between the 2
groups.
You do not tell us in your presentation or in the manuscript
whether or not there was left anterior descending disease in those
26 patients and whether or not they were saphenous vein bypasses.
Can you comment on that?gery c November 2012
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computed tomography angiography before the procedure as we
mentioned. In those data, whenever we find coronary artery dis-
ease that actually went to a repair, those patients were excluded.
That was 1 of the factors why this comparison group was small.
I think your suggestion that 26 patients is a very small comparison
group is totally valid. My ideal comparison group would have been
a dissected LITA group and compare those 2 with showing a better
outcome in the no-dissection technique. However, in our institu-
tion, this technique is standard and I was only able to find 6 patients
with a dissected LITA. This was an even lower number to compare.
That is why we used this as a comparison group.
Dr Shemin. Another interesting data point that came to my at-
tention was the fact that the cardiopulmonary bypass time in the 2
groups was similar. I cannot understand that if in half the patients
you cannulated the groin went on to bypass before opening the
chest, cooled to 20 degrees, and then had to rewarm, how could
you have a similar time on bypass to a group of patients in
whom you just opened the chest? I assume that the cooling was
a routine 30 to 34 degrees, so the warming and cooling time would
obviously not be anywhere as long.
Dr Kaneko. The initiation of cardiopulmonary bypass was
completely surgeon dependent. In the data before 2002, it was
our standard practice to initiate a cardiopulmonary bypass before
doing the resternotomy. In the recent patients that at least I have
seen, we perform a sternotomy under no cardiopulmonary bypass;
however, they are cannulated and, as soon as the mediastinal dis-
section gets difficult, we started cooling, which like you said might
take time, but that will eliminate some of the time that is used in the
sternotomy time. Also, there was a slight difference, although sta-
tistically nonsignificant (5 minute shorter time), in the crossclamp
time. Our belief is that, hopefully, shorter crossclamp time is con-
tributing to that as well.
Dr Shemin. Okay. I do not quite buy it but—I mean it usually
takes 45 minutes to an hour to cool somebody to 20 degrees and
sometimes at least 1-and-a-half to twice as long to rewarm them,
so I think, again, the comparison group is somewhat detracting
from the message of the good results in your study.
The same thing with adequacy and myocardial protection: In
your manuscript, you mentioned that 22 patients, or 12.5%, re-
quired a balloon pump and 21 of those 22 were put in intraopera-
tively whereas, in the ‘‘comparison group,’’ it was only 2 patients
or 7%. Were these balloons put in for high-dose inotropes and
power failure, suggesting that maybe the myocardial protection
despite your creatine phosphokinase data were not quite as good
as you are leading us to believe?
DrKaneko.Therewere 2 patients who had a preoperative intra-
aortic balloon pump, but, yes, there are more patients who received
intra-aortic balloon pump during the case in the no-dissection
group. We do not have a good explanation for that. We were trying
to look at the inotropes along with the balloon pump to see if that
will correlate the need and possibly reflect the myocardial protec-
tion, but those values were not really available. That is one of the
weaknesses of the findings that we had.
Dr Shemin. You also mentioned in the manuscript that very of-
ten with the thoracic artery being patent that placing the sutures inThe Journal of Thoracic and Carthe annulus can sometimes be obscured particularly in the left
main coronary artery because of backflow, and you would have
to go down to flow rates between 500 and 1500. Can you say
how often that was done and for what period of time because the
stroke rate was 2.2%, which probably is quite acceptable but I
am just interested in how much low-flow perfusion was necessary
just to technically perform the suturing.
Dr Kaneko. When we placed the suction right at the coronary
ostium, unless you are putting a stitch right around that area, it is
usually pretty visible. I think the visual field is okay. We only have
to stop the pump maybe once or twice if the stitch is right at the
coronary ostium on the left side. That has been the usual case
that I have seen.
Dr Shemin. And my last question—I think everyone in the au-
dience understands hypothermia, but tell us a little bit about hyper-
kalemia, systemic hyperkalemia: To what level, how did you
achieve it, what do you do with people with renal failure? Is there
a contraindication to this technique?
Dr Kaneko. How we usually do it is we place 40 mEq of potas-
sium chloride into the pump. Our goal is above 6 but not going over
7. Usually, after 40 mEq, we were able to maintain that level. The
only time that we had to give further potassiumwas when the myo-
cardium starting moving.When there is activity, we usually add 10
to 20 mEq to control that, and that has worked pretty well. I did not
include this in the slides but we had 3 patients in the no-dissection
group who had dialysis after surgery, which equals about 2% in the
whole population. That is comparable to some of the other groups
that we have studied, so I do not think there is an increase in the
renal failure patients and, usually after the surgery at the end of
a case using ultra-filtration, potassium level is around 5. After di-
uresis by cardiopulmonary bypass, their potassium level goes to
a normal level within 24 hours.
Dr Shemin.You certainly have all that warming time to get that
potassium back down to normal.
Congratulations on a nice presentation and I thank the Western
for the opportunity to discuss this paper.
Dr John Ikonomidis (Charleston, SC). I enjoyed the presenta-
tion a lot. I have a question about the incidence of ventricular fibril-
lation in the no-dissection group.
I did not catch it in your presentation but did you record the in-
cidence of ventricular fibrillation, how long it occurred? You did
not give us any information about administration of cardioplegia
in terms of frequency. In the no-dissection group, did you give car-
dioplegia more often to try and counteract that? Also, what about
administration of antiarrhythmics in those patients? Could you
comment on those issues?
Dr Kaneko. The cardioplegia technique was surgeon prefer-
ence and about half of the patients received antegrade and half
that received antegrade and retrograde.
Ventricular fibrillation was seen especially when the patient was
hypothermic. At around 20 degrees there is usually no myocardial
activity and at around 25 or 26, when we see a fibrillation, we add
potassium to stop that activity at that time.
As far as antiarrhythmics, it is not our routine to use them in our
institutions. However, if we see a ventricular tachycardia, we do
give lidocaine in the pump and that is our standard practice, yes.diovascular Surgery c Volume 144, Number 5 1041
